BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 32951065)

  • 21. MR-imaging features of hepatocellular carcinoma capsule appearance in cirrhotic liver: comparison of gadoxetic acid and gadobenate dimeglumine.
    Dioguardi Burgio M; Picone D; Cabibbo G; Midiri M; Lagalla R; Brancatelli G
    Abdom Radiol (NY); 2016 Aug; 41(8):1546-54. PubMed ID: 27052455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liver Imaging Reporting and Data System with MR Imaging: Evaluation in Nodules 20 mm or Smaller Detected in Cirrhosis at Screening US.
    Darnell A; Forner A; Rimola J; Reig M; García-Criado Á; Ayuso C; Bruix J
    Radiology; 2015 Jun; 275(3):698-707. PubMed ID: 25658038
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Longitudinal evolution of CT and MRI LI-RADS v2014 category 1, 2, 3, and 4 observations.
    Hong CW; Park CC; Mamidipalli A; Hooker JC; Fazeli Dehkordy S; Igarashi S; Alhumayed M; Kono Y; Loomba R; Wolfson T; Gamst A; Murphy P; Sirlin CB
    Eur Radiol; 2019 Sep; 29(9):5073-5081. PubMed ID: 30809719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of gadobenate dimeglumine-enhanced MR findings for characterizing small (1-2-cm) hepatic nodules in patients at high risk for hepatocellular carcinoma.
    Kim TK; Lee KH; Jang HJ; Haider MA; Jacks LM; Menezes RJ; Park SH; Yazdi L; Sherman M; Khalili K
    Radiology; 2011 Jun; 259(3):730-8. PubMed ID: 21364083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic performance of MR for hepatocellular carcinoma based on LI-RADS v2018, compared with v2017.
    Ren AH; Zhao PF; Yang DW; Du JB; Wang ZC; Yang ZH
    J Magn Reson Imaging; 2019 Sep; 50(3):746-755. PubMed ID: 30648327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical implication of small (<20 mm) enhancing hepatic nodules observed only during three-dimensional gadobenate dimeglumine-enhanced hepatic arterial-phase MRI of the hepatitis B virus-induced mild cirrhosis.
    Kim YK; Lee YH; Kwak HS; Kim CS; Han YM
    Clin Imaging; 2008; 32(6):453-9. PubMed ID: 19006774
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New Arterial Phase Enhancing Nodules on MRI of Cirrhotic Liver: Risk of Progression to Hepatocellular Carcinoma and Implications for LI-RADS Classification.
    Smereka P; Doshi AM; Lavelle LP; Shanbhogue K
    AJR Am J Roentgenol; 2020 Aug; 215(2):382-389. PubMed ID: 32432909
    [No Abstract]   [Full Text] [Related]  

  • 28. Diagnostic accuracy of prospective application of the Liver Imaging Reporting and Data System (LI-RADS) in gadoxetate-enhanced MRI.
    Kim YY; An C; Kim S; Kim MJ
    Eur Radiol; 2018 May; 28(5):2038-2046. PubMed ID: 29230525
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic Performance of LI-RADS Version 2018, LI-RADS Version 2017, and OPTN Criteria for Hepatocellular Carcinoma.
    Kierans AS; Song C; Gavlin A; Roudenko A; Lu L; Askin G; Hecht EM
    AJR Am J Roentgenol; 2020 Nov; 215(5):1085-1092. PubMed ID: 32877248
    [No Abstract]   [Full Text] [Related]  

  • 30. Usefulness of combining sequentially acquired gadobenate dimeglumine-enhanced magnetic resonance imaging and resovist-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: comparison with computed tomography hepatic arteriography and computed tomography arterioportography using 16-slice multidetector computed tomography.
    Kim YK; Kwak HS; Han YM; Kim CS
    J Comput Assist Tomogr; 2007; 31(5):702-11. PubMed ID: 17895780
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resolution of indeterminate MRI with CEUS in patients at high risk for hepatocellular carcinoma.
    Hu J; Bhayana D; Burak KW; Wilson SR
    Abdom Radiol (NY); 2020 Jan; 45(1):123-133. PubMed ID: 31440801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liver Imaging Reporting and Data System:: Substantial Discordance Between CT and MR for Imaging Classification of Hepatic Nodules.
    Zhang YD; Zhu FP; Xu X; Wang Q; Wu CJ; Liu XS; Shi HB
    Acad Radiol; 2016 Mar; 23(3):344-52. PubMed ID: 26777590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium-enhanced MRI.
    Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
    Radiology; 2019 Sep; 292(3):655-663. PubMed ID: 31310175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of CEUS LI-RADS for the Accurate Diagnosis of Nodules in Patients at Risk for Hepatocellular Carcinoma: A Validation Study.
    Makoyeva A; Kim TK; Jang HJ; Medellin A; Wilson SR
    Radiol Imaging Cancer; 2020 Mar; 2(2):e190014. PubMed ID: 33778701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liver Imaging Reporting and Data System: Patient Outcomes for Category 4 and 5 Nodules.
    Choi SH; Byun JH; Lim YS; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
    Radiology; 2018 May; 287(2):515-524. PubMed ID: 29457964
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence of diagnostic enhancement pattern in hepatocellular carcinoma nodules ≤2 cm according to the AASLD/EASL revised criteria.
    Quaia E; De Paoli L; Angileri R; Pizzolato R; Cabibbo B; Cova MA
    Abdom Imaging; 2013 Dec; 38(6):1245-53. PubMed ID: 24026173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differentiating hepatocellular carcinoma from dysplastic nodules at gadobenate dimeglumine-enhanced hepatobiliary-phase magnetic resonance imaging.
    Gatto A; De Gaetano AM; Giuga M; Ciresa M; Siciliani L; Miele L; Riccardi L; Pizzolante F; Rapaccini GL; Gasbarrini A; Giuliante F; Vecchio FM; Pompili M; Bonomo L
    Abdom Imaging; 2013 Aug; 38(4):736-44. PubMed ID: 22986351
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS.
    Schellhaas B; Görtz RS; Pfeifer L; Kielisch C; Neurath MF; Strobel D
    Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1036-1044. PubMed ID: 28562394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MRI Ancillary Features for LI-RADS Category 3 and 4 Observations: Improved Categorization to Indicate the Risk of Hepatic Malignancy.
    Kim YY; Choi JY; Kim SU; Lee M; Park MS; Chung YE; Kim MJ
    AJR Am J Roentgenol; 2020 Dec; 215(6):1354-1362. PubMed ID: 33052732
    [No Abstract]   [Full Text] [Related]  

  • 40. LI-RADS to categorize liver nodules in patients at risk of HCC: tool or a gadget in daily practice?
    Barabino M; Gurgitano M; Fochesato C; Angileri SA; Franceschelli G; Santambrogio R; Mariani NM; Opocher E; Carrafiello G
    Radiol Med; 2021 Jan; 126(1):5-13. PubMed ID: 32458272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.